Alzforum: Drugs In Clinical Trials - Exelon™HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc. A phenyl-carbamate derivative, a brain-selective acetylcholinesterase inhibitor, thought to selectively target hippocampus and cerebral cortex. Studies in lesioned rats indicate that ENA-713 ameliorates impairment of ChAT activity. Rivastigmine preferentially inhibits the G1 enzymatic form of AChE, which predominates in the brains of patients with Alzheimer's disease (AD). At the high dose of 12 mg.day (note, in this study, 10% of the patients discontinued the study on the medication because of severe nausea and vomiting). Nausea (40% vs. 10% placebo); dizziness (40% vs. 30%); fatigue (25% vs. 0%); myalgia (20% vs. 0%); urinary incontinence(20% vs. 0%); sweating (10% vs. 0%); vision disorders (15% vs. 0%). Rivastigmine causes adverse events that are generally those expected from an acetylcholinesterase inhibitor. They are usually mild to moderate, of short duration and responsive to dosage reduction. One case of severe vomiting with esophageal rupture reported to have occurred after reinitiation of treatment at an inappropriate single dose of 4.5 mg following an interruption of treatment for eight weeks.
VS RIVASTIGMINE
reminyl in
